Base de dados : MEDLINE
Pesquisa : D08.811.277.656.300.760.442 [Categoria DeCS]
Referências encontradas : 7978 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 798 ir para página                         

  1 / 7978 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453701
[Au] Autor:Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
[Ad] Endereço:Departments of Medicine and Urology, Tulane Cancer Center, New Orleans, USA.
[Ti] Título:An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
[So] Source:Ann Oncol;28(5):1090-1097, 2017 05 01.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not established. Patients and methods: The radium-223 ALSYMPCA trial enrolled patients with CRPC and symptomatic bone metastases. Prognostic potential of baseline variables was assessed using Cox models. Percentage changes in biomarker levels from baseline were evaluated during the trial period; changes from baseline to week 12 were evaluated for association with OS and surrogacy. Results: Eastern Cooperative Oncology Group performance status, total alkaline phosphatase (tALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) at baseline were associated with OS (P ≤ 0.0003) in the intent-to-treat population (radium-223, N = 614; placebo, N = 307). tALP declined from baseline within 4 weeks after beginning radium-223, by week 12 declining in 87% of radium-223 and 23% of placebo patients (P < 0.001). LDH declined in 51% and 34% (P = 0.003), whereas PSA declined in 27% and 14% (P = 0.160). Mean tALP change from baseline was 32.2% decrease with radium-223 and 37.2% increase with placebo. Radium-223 patients with tALP decline from baseline to week 12 (confirmed ≥3 weeks from week 12) had 55% lower risk of death (hazard ratio = 0.45; 95% CI 0.34-0.61) versus those with no confirmed tALP decline. Proportional treatment effect (PTE) values for tALP, LDH, and PSA changes from baseline at week 12 as OS surrogate markers were 0.34 (95% CI: 0-0.746), 0.07 (95% CI: 0-0.211), and 0 (95% CI: 0-0.082), respectively. Conclusions: Significant tALP declines (versus placebo) occurred as early as 4 weeks after beginning radium-223 therapy. tALP or LDH declines at 12 weeks correlated with longer OS, but did not meet statistical surrogacy requirements. Dynamic changes in tALP and LDH during radium-223 treatments may be useful to monitor, but do not serve as surrogates for survival.
[Mh] Termos MeSH primário: Neoplasias de Próstata Resistentes à Castração/radioterapia
Compostos Radiofarmacêuticos/uso terapêutico
Rádio (Elemento)/uso terapêutico
[Mh] Termos MeSH secundário: Fosfatase Alcalina/metabolismo
Biomarcadores Tumorais/metabolismo
Seres Humanos
Calicreínas/metabolismo
Estimativa de Kaplan-Meier
L-Lactato Desidrogenase/metabolismo
Masculino
Análise Multivariada
Prognóstico
Modelos de Riscos Proporcionais
Antígeno Prostático Específico/metabolismo
Neoplasias de Próstata Resistentes à Castração/enzimologia
Neoplasias de Próstata Resistentes à Castração/mortalidade
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Radiopharmaceuticals); 0 (Radium-223); EC 1.1.1.27 (L-Lactate Dehydrogenase); EC 3.1.3.1 (Alkaline Phosphatase); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen); W90AYD6R3Q (Radium)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdx044


  2 / 7978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453693
[Au] Autor:Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
[Ad] Endereço:Harvard Radiation Oncology Program, Boston, USA.
[Ti] Título:Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
[So] Source:Ann Oncol;28(5):1098-1104, 2017 05 01.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: In 2012, the United States Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA) screening, despite evidence that Black men are at a higher risk of prostate cancer-specific mortality (PCSM). We evaluated whether Black men of potentially screening-eligible age (55-69 years) are at a disproportionally high risk of poor outcomes. Patients and methods: The SEER database was used to study 390 259 men diagnosed with prostate cancer in the United States between 2004 and 2011. Multivariable logistic regression modeled the association between Black race and stage of presentation, while Fine-Gray competing risks regression modeled the association between Black race and PCSM, both as a function of screening eligibility (age 55-69 years versus not). Results: Black men were more likely to present with metastatic disease (adjusted odds ratio [AOR] 1.65; 1.58-1.72; P < 0.001) and were at a higher risk of PCSM (adjusted hazard ratio [AHR] 1.36; 1.27-1.46; P < 0.001) compared to non-Black men. There were significant interactions between race and PSA-screening eligibility such that Black patients experienced more disproportionate rates of metastatic disease (AOR 1.76; 1.65-1.87 versus 1.55; 1.47-1.65; Pinteraction < 0.001) and PCSM (AHR 1.53; 1.37-1.70 versus 1.25; 1.14-1.37; Pinteraction = 0.01) in the potentially PSA-screening eligible group than in the group not eligible for screening. Conclusions: Racial disparities in prostate cancer outcome among Black men are significantly worse in PSA-screening eligible populations. These results raise the possibility that Black men could be disproportionately impacted by recommendations to end PSA screening in the United States and suggest that Black race should be included in the updated USPSTF PSA screening guidelines.
[Mh] Termos MeSH primário: Neoplasias da Próstata/diagnóstico
[Mh] Termos MeSH secundário: Afroamericanos
Idoso
Detecção Precoce de Câncer
Disparidades em Assistência à Saúde
Seres Humanos
Calicreínas/metabolismo
Masculino
Meia-Idade
Modelos de Riscos Proporcionais
Antígeno Prostático Específico/metabolismo
Neoplasias da Próstata/metabolismo
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/terapia
Fatores de Risco
Programa de SEER
Resultado do Tratamento
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdx041


  3 / 7978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29321194
[Au] Autor:Seibert TM; Fan CC; Wang Y; Zuber V; Karunamuni R; Parsons JK; Eeles RA; Easton DF; Kote-Jarai Z; Al Olama AA; Garcia SB; Muir K; Grönberg H; Wiklund F; Aly M; Schleutker J; Sipeky C; Tammela TL; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Røder MA; Iversen P; Key TJ; Travis RC; Neal DE; Donovan JL; Hamdy FC; Pharoah P; Pashayan N; Khaw KT; Maier C; Vogel W; Luedeke M; Herkommer K; Kibel AS; Cybulski C; Wokolorczyk D; Kluzniak W; Cannon-Albright L; Brenner H; Cuk K; Saum KU; Park JY; Sellers TA; Slavov C; Kaneva R; Mitev V; Batra J; PRACTICAL Consortium*
[Ad] Endereço:Center for Multimodal Imaging and Genetics, University of California, San Diego, La Jolla, CA, USA tseibert@ucsd.edu amdale@ucsd.edu.
[Ti] Título:Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
[So] Source:BMJ;360:j5757, 2018 01 10.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction of survival free from PCa. SETTING: Multiple institutions that were members of international PRACTICAL consortium. PARTICIPANTS: All consortium participants of European ancestry with known age, PCa status, and quality assured custom (iCOGS) array genotype data. The development dataset comprised 31 747 men; the validation dataset comprised 6411 men. MAIN OUTCOME MEASURES: Prediction with hazard score of age of onset of aggressive cancer in validation set. RESULTS: In the independent validation set, the hazard score calculated from 54 single nucleotide polymorphisms was a highly significant predictor of age at diagnosis of aggressive cancer (z=11.2, P<10 ). When men in the validation set with high scores (>98th centile) were compared with those with average scores (30th-70th centile), the hazard ratio for aggressive cancer was 2.9 (95% confidence interval 2.4 to 3.4). Inclusion of family history in a combined model did not improve prediction of onset of aggressive PCa (P=0.59), and polygenic hazard score performance remained high when family history was accounted for. Additionally, the positive predictive value of PSA screening for aggressive PCa was increased with increasing polygenic hazard score. CONCLUSIONS: Polygenic hazard scores can be used for personalised genetic risk estimates that can predict for age at onset of aggressive PCa.
[Mh] Termos MeSH primário: Detecção Precoce de Câncer/métodos
Calicreínas/análise
Polimorfismo de Nucleotídeo Único/genética
Antígeno Prostático Específico/análise
Neoplasias da Próstata/sangue
Neoplasias da Próstata/genética
[Mh] Termos MeSH secundário: Idade de Início
Idoso
Estudos de Coortes
Intervalo Livre de Doença
Grupo com Ancestrais do Continente Europeu/genética
Genótipo
Seres Humanos
Masculino
Meia-Idade
Avaliação de Resultados (Cuidados de Saúde)
Valor Preditivo dos Testes
Neoplasias da Próstata/diagnóstico
Medição de Risco
Análise de Sobrevida
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5757


  4 / 7978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29229389
[Au] Autor:Perez VA; Mangum JE; Hubbard MJ
[Ad] Endereço:Department of Pharmacology & Therapeutics, The University of Melbourne, Victoria, Australia; Department of Pediatric Stomatology, University of Talca, Talca, Chile.
[Ti] Título:Direct evidence that KLK4 is a hydroxyapatite-binding protein.
[So] Source:Biochem Biophys Res Commun;495(2):1896-1900, 2018 01 08.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The protease kallikrein 4 (KLK4) plays a pivotal role during dental enamel formation by degrading the major enamel protein, amelogenin, prior to the final steps of enamel hardening. KLK4 dysfunction is known to cause some types of developmental defect in enamel but the mechanisms responsible for transient retention of KLK4 in semi-hardened enamel matrix remain unclear. To address contradictory reports about the affinity of KLK4 for enamel hydroxyapatite-like mineral, we used pure components in quasi-physiological conditions and found that KLK4 binds hydroxyapatite directly. Hypothesising KLK4 self-destructs once amelogenin is degraded, biochemical analyses revealed that KLK4 progressively lost activity, became aggregated, and autofragmented when incubated without substrate in both the presence and absence of reducer. However, with non-ionic detergent present as proxy substrate, KLK4 remained active and intact throughout. These findings prompt a new mechanistic model and line of enquiry into the role of KLK4 in enamel hardening and malformation.
[Mh] Termos MeSH primário: Esmalte Dentário/química
Esmalte Dentário/ultraestrutura
Durapatita/química
Calicreínas/química
Calicreínas/ultraestrutura
[Mh] Termos MeSH secundário: Sítios de Ligação
Ativação Enzimática
Estabilidade Enzimática
Ligação Proteica
Especificidade por Substrato
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
91D9GV0Z28 (Durapatite); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein 4)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE


  5 / 7978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743596
[Au] Autor:Weidmann H; Heikaus L; Long AT; Naudin C; Schlüter H; Renné T
[Ad] Endereço:Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
[Ti] Título:The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity.
[So] Source:Biochim Biophys Acta;1864(11 Pt B):2118-2127, 2017 11.
[Is] ISSN:0006-3002
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The contact system is a potent procoagulant and proinflammatory plasma protease cascade that is initiated by binding ("contact")-induced, auto-activation of factor XII zymogen. Formed active serine protease FXIIa then cleaves plasma prekallikrein to kallikrein that in turn liberates the mediator bradykinin from its precursor high molecular weight kininogen. Bradykinin induces inflammation with implications for host defense and innate immunity. FXIIa also triggers the intrinsic pathway of coagulation that has been shown to critically contribute to thrombosis. Vice versa, FXII deficiency impairs thrombosis in animal models without inducing abnormal excessive bleeding. Recent work has established the FXIIa-driven contact system as promising target for anticoagulant and anti-inflammatory drugs. This review focuses on the biochemistry of the contact system, its regulation by endogenous and exogenous inhibitors, and roles in disease states. This article is part of a Special Issue entitled: Proteolysis as a Regulatory Event in Pathophysiology edited by Stefan Rose-John.
[Mh] Termos MeSH primário: Coagulação Sanguínea/genética
Deficiência do Fator XII/genética
Fator XIIa/genética
Inflamação/genética
[Mh] Termos MeSH secundário: Bradicinina/genética
Deficiência do Fator XII/sangue
Deficiência do Fator XII/patologia
Seres Humanos
Imunidade Inata/genética
Inflamação/sangue
Inflamação/patologia
Calicreínas/genética
Trombose/sangue
Trombose/genética
Trombose/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
EC 3.4.21.- (Kallikreins); EC 3.4.21.38 (Factor XIIa); S8TIM42R2W (Bradykinin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  6 / 7978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29283518
[Au] Autor:Ivanova VV; Milto IV; Sukhodolo IV; Serebryakova ON; Buzenkova AV
[Ti] Título:Digestive and Nondigestive Functions of Rodents' Salivary Glands.
[So] Source:Usp Fiziol Nauk;48(1):66-79, 2017 Jan-Mar.
[Is] ISSN:0301-1798
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Major salivary glands play a role not only in digestion, but also in regulation of other functions in rodents. In this review, we analyzed and summarized the data about the rodents' parotid, submandibular and sublingual salivary glands functions, which is not limited to the production of saliva and action of its hydrolytic enzymes on food in the oral cavity. In recent decades significantly expanded understanding of major salivary glands nondigestive functions. They are involved in excretion of metabolic products, maintaining fluid and electrolyte balance. Special attention has been paid to the characteristics of specific (parotin, sialorphin, etc.) and nonspecific (epidermal growth factor, nerve growth factor, kallikrein, etc.) active substances of the major salivary glands and their involvement in wound healing, mineral metabolism, regulation of hematopoiesis and immunity system. Summarized and analyzed major salivary glands endocrine function in the organs and systems. Available literature data suggest: the structure of the major salivary glands, as well as the synthesis and secretion of a number of biologically active substances are controlled by sex hormones. In turn, these biologically active factors of the salivary glands, as epidermal growth factor, and parotin, sialorphin, whose expression is regulated by androgens, have an impact on the morphological and functional state of the gonads. Thus, major salivary glands operate a wide range of functions and involved in the regulation of sexual behavior of reproductive function and maintaining homeostasis in the body.
[Mh] Termos MeSH primário: Glândula Parótida/fisiologia
Roedores/fisiologia
Proteínas e Peptídeos Salivares/metabolismo
Glândula Sublingual/fisiologia
Glândula Submandibular/fisiologia
[Mh] Termos MeSH secundário: Animais
Fator de Crescimento Epidérmico/genética
Fator de Crescimento Epidérmico/metabolismo
Regulação da Expressão Gênica
Hormônios Esteroides Gonadais/genética
Hormônios Esteroides Gonadais/metabolismo
Hematopoese/fisiologia
Imunidade Inata/efeitos dos fármacos
Calicreínas/genética
Calicreínas/metabolismo
Fator de Crescimento Neural/genética
Fator de Crescimento Neural/metabolismo
Saliva/química
Saliva/fisiologia
Proteínas e Peptídeos Salivares/genética
Proteínas e Peptídeos Salivares/farmacologia
Equilíbrio Hidroeletrolítico/fisiologia
Cicatrização/efeitos dos fármacos
Cicatrização/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadal Steroid Hormones); 0 (Salivary Proteins and Peptides); 62229-50-9 (Epidermal Growth Factor); 9061-61-4 (Nerve Growth Factor); EC 3.4.21.- (Kallikreins)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171229
[St] Status:MEDLINE


  7 / 7978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982907
[Au] Autor:Macchia G; Siepe G; Capocaccia I; Nguyen NP; Schiavina R; Cammelli S; Guerri S; Arcelli A; Buwenge M; Ntreta M; Cilla S; Valentini V; Deodato F; Morganti AG
[Ad] Endereço:Radiotherapy Unit, Giovanni Paolo II, Sacred Heart Catholic University, Campobasso, Italy.
[Ti] Título:Hypofractionated Postoperative IMRT in Prostate Carcinoma: A Phase I/II Study.
[So] Source:Anticancer Res;37(10):5821-5828, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT). PATIENTS AND METHODS: A total of 124 patients with PCa at high risk of relapse after RP or diagnosis of biochemical relapse were included. Patients received 62.5 Gy to the prostate bed and 45 Gy to pelvic nodes in 25 fractions. Androgen-suppressive therapy was prescribed based on National Comprehensive Cancer Network risk categories. RESULTS: Median follow-up was 30 months. Only two patients (1.6%) developed grade 3 or more acute toxicity: one grade 3 skin toxicity (0.8%) and one grade 4 genitourinary toxicity (0.8%). Grade 2 acute gastrointestinal and genitourinary toxicity was recorded in 24.2% and 17.7% of patients, respectively. Five-year grade 2 or more gastrointestinal and genitourinary toxicity was 1.1% and 7.3%, respectively. Five-year biochemical relapse-free survival was 86.5%. CONCLUSION: After RP, hypofractionated IMRT-SIB demonstrated a favorable toxicity profile and encouraging results in terms of relapse-free survival.
[Mh] Termos MeSH primário: Radioterapia Hipofracionada
Prostatectomia
Neoplasias da Próstata/terapia
Radioterapia de Intensidade Modulada/métodos
[Mh] Termos MeSH secundário: Idoso
Antagonistas de Androgênios/uso terapêutico
Quimiorradioterapia Adjuvante
Intervalo Livre de Doença
Seres Humanos
Calicreínas/sangue
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Estudos Prospectivos
Antígeno Prostático Específico/sangue
Prostatectomia/efeitos adversos
Neoplasias da Próstata/sangue
Neoplasias da Próstata/patologia
Radioterapia de Intensidade Modulada/efeitos adversos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  8 / 7978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982897
[Au] Autor:Iwama K; Yamazaki H; Shimizu D; Suzuki G; Nakamura S; Sasaki N; Takeneka T; Okabe H; Nishikawa T; Yoshida K
[Ad] Endereço:Department of Radiology, Ujitakeda Hospital, Uji, Japan.
[Ti] Título:Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.
[So] Source:Anticancer Res;37(10):5755-5760, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: To investigate the correlation between frequency of action level of interfractional rectal displacement requiring repeated precaution in patients with prostate cancer and late toxicity from image-guided intensity-modulated radiation therapy (IG-IMRT) using helical tomotherapy. PATIENTS AND METHODS: We examined 264 patients who underwent IG-IMRT during 2007-2011. Megavoltage computed tomographic (MVCT) images were acquired before radiation therapy and was examined with soft-tissue matching by comparing treatment planning images within 9,345 fractions. Displacement of the anterior rectal region larger than 5 mm, requiring repeated precaution, was defined as the level of rectal displacement requiring action (ARD). RESULTS: ARD was identified in 815 (7.7%) out of 9,345 fractions and at least once in 82% (216/264) of patients. The highest incidence of ARD (11%) was found during the initial week of treatment (first five and next five fractions), after which the incidence decreased to 6% (p<0.0001). Patients with lean body (lower body mass index (BMI) tended to have a higher incidence of ARD. We identified 16 (6%) cases of gastrointestinal toxicity and 12 (4.5%) genitourinary toxicities as a late adverse reaction (3 months or later after IG-IMRT). There was no correlation between ARD and late toxicity. Prostate-specific antigen (PSA) control was also similar (p=0.12) between those with ARD (96% at 5 year) and those without ARD (88%). CONCLUSION: ARD occurred predominantly in lean patients, during the initial week of treatment and became less likely over time. ARD was not correlated to late toxicity and PSA control, therefore, IG-IMRT technique was able to adequately control error due to interfractional prostate and rectal motion.
[Mh] Termos MeSH primário: Órgãos em Risco/efeitos da radiação
Neoplasias da Próstata/radioterapia
Lesões por Radiação/prevenção & controle
Planejamento da Radioterapia Assistida por Computador/métodos
Radioterapia Guiada por Imagem/métodos
Radioterapia de Intensidade Modulada/métodos
Reto/efeitos da radiação
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Fracionamento de Dose
Seres Humanos
Calicreínas/sangue
Masculino
Meia-Idade
Órgãos em Risco/diagnóstico por imagem
Valor Preditivo dos Testes
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/sangue
Neoplasias da Próstata/diagnóstico por imagem
Neoplasias da Próstata/patologia
Lesões por Radiação/tratamento farmacológico
Lesões por Radiação/etiologia
Radioterapia Guiada por Imagem/efeitos adversos
Radioterapia de Intensidade Modulada/efeitos adversos
Reto/diagnóstico por imagem
Estudos Retrospectivos
Medição de Risco
Fatores de Risco
Fatores de Tempo
Tomografia Computadorizada Espiral
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  9 / 7978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982844
[Au] Autor:Hutchinson J; Marignol L
[Ad] Endereço:Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin, Ireland.
[Ti] Título:Clinical Potential of Statins in Prostate Cancer Radiation Therapy.
[So] Source:Anticancer Res;37(10):5363-5372, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Statins are cholesterol- lowering drugs that have been shown to possess anti-tumour properties. Observational studies have shown that 3-hydroxy-3-methlyglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced prostate cancer risk. Preclinical studies suggest that statins possess anticancer and radiosensitising properties. This review aims to determine the impact of statin use in the efficacy of radiation therapy and the therapeutic window in prostate cancer. MATERIALS AND METHODS: The scientific databases PubMed, Science Direct, EMBASE, Cochrane Collaboration, and Google Scholar were searched for articles identifying statin use in histologically confirmed prostate cancer treated with external beam radiation therapy. RESULTS: Improvement was observed in freedom from biochemical failure (91% vs. 79%), relapse free survival (72% vs. 69%), distant metastasis free survival (96% vs. 94%), and prostate-specific antigen (PSA) relapse free survival (89% vs. 83%) with statin use, however this did not translate into an overall survival benefit for patients. Conflicting data concerning clinical outcomes reduce the integrity of these findings. The literature supports the radiosensitising properties of statins and their potential antitumor effects in prostate cancer. CONCLUSION: Statin use in prostate cancer presents many obstacles yet to be overcome, which warrant attention prior to the routine implementation of statins in treatment regimes. However, there is evidence to support their beneficial use.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Quimiorradioterapia/métodos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Neoplasias da Próstata/terapia
Radiossensibilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/efeitos adversos
Quimiorradioterapia/efeitos adversos
Progressão da Doença
Intervalo Livre de Doença
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos
Calicreínas/sangue
Masculino
Metástase Neoplásica
Recidiva Local de Neoplasia
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/sangue
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/patologia
Radiossensibilizantes/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Radiation-Sensitizing Agents); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  10 / 7978 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28980836
[Au] Autor:Franzese C; Lopci E; Di Brina L; D'Agostino GR; Navarria P; Mancosu P; Tomatis S; Chiti A; Scorsetti M
[Ad] Endereço:a Radiotherapy and Radiosurgery , Humanitas Clinical and Research Center , Via Manzoni Rozzano ( Milano ) - Italy.
[Ti] Título:11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer.
[So] Source:Cancer Invest;35(9):586-593, 2017 Oct 21.
[Is] ISSN:1532-4192
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: aim is outcome of 11C-Choline-PET guided SBRT on lymph node metastases. MATERIALS AND METHODS: patients with 1 - 4 lymph node metastases detected by 11C-choline-PET were treated with SBRT. Toxicity, treated metastases control and Progression Free Survival were computed. RESULTS: twenty-six patients, 38 lymph node metastases were irradiated. No grade ≥ 2 toxicity. Median PSA-nadir after RT was 1.02 ng/mL. Post-treatment 11C-Choline-PET showed metabolic complete response in 17 metastases (44,7%), partial response in 9 metastases (38%). CONCLUSION: SBRT is effective and safe for lymph node metastases. PET is important in identification of gross tumor and evaluation of the response.
[Mh] Termos MeSH primário: Radioisótopos de Carbono/administração & dosagem
Colina/administração & dosagem
Linfonodos/cirurgia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Neoplasias da Próstata/cirurgia
Compostos Radiofarmacêuticos/administração & dosagem
Radiocirurgia/métodos
[Mh] Termos MeSH secundário: Idoso
Intervalo Livre de Doença
Seres Humanos
Calicreínas/sangue
Estimativa de Kaplan-Meier
Linfonodos/diagnóstico por imagem
Linfonodos/patologia
Metástase Linfática
Masculino
Valor Preditivo dos Testes
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/sangue
Neoplasias da Próstata/diagnóstico por imagem
Neoplasias da Próstata/patologia
Radiocirurgia/efeitos adversos
Estudos Retrospectivos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carbon Radioisotopes); 0 (Radiopharmaceuticals); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen); N91BDP6H0X (Choline)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171006
[St] Status:MEDLINE
[do] DOI:10.1080/07357907.2017.1375116



página 1 de 798 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde